Navigation Links
Moving gene therapy forward with mobile DNA
Date:5/3/2009

Gene therapy

Gene therapy is the introduction of genetic material into a patient's cells resulting in a cure or a therapeutic effect. In recent years, it has been shown that gene therapy is a promising technology to treat or even cure several fatal diseases for which there is no attractive alternative therapy. Gene therapy can be used for hereditary diseases, but also for other diseases that affect heart, brain and even for cancer. Indeed, recent results suggest that gene therapy can be beneficial for patients suffering from aggressive brain cancer that would otherwise be lethal.

A safe delivery of the genes?

Despite the overall progress, there is still a need to develop improved and safer approaches to deliver genes into cells. The success of gene therapy ultimately depends on these gene delivery vehicles or vectors. Most vectors have been derived from virusses that can be tailor-made to deliver therapeutic genes into the patients' cells. However, some of these viral vectors can induce side-effects, including cancer and inflammation.

Marinee Chuah, Thierry VandenDriessche, Eyayu Belay and their fellow VIB researchers at K.U. Leuven in collaboration with Zsuzsanna Iszvak and Zoltan Ivics and colleagues at the Max Delbrck Center in Berlin (Germany) have now developed a new non-viral approach that overcomes some of the limitations associated with viral vectors.

Lessons from evolution

Using the principles of evolution and natural selection, that were initially conceived by Charles Darwin, they have now developped an efficient and safe gene delivery approach based on non-viral genetic elements, called transposons. Transposons are mobile DNA elements that can integrate into 'foreign' DNA via a 'cut-and-paste' mechanism. In a way they are natural gene delivery vehicles. The researchers constructed the transposons in such a way that they can carry the therapeutic gene into the target cell DNA. Doing so,
'/>"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related biology news :

1. ORNL study finds rivers play part in removing nitrogen
2. Iron-moving malfunction may underlie neurodegenerative diseases, aging
3. Scientists present moving theory behind bacterial decision-making
4. Moving new technologies from the lab to the marketplace
5. Moving in for the winter toxic brown recluse spiders pose danger
6. A new radiation therapy treatment developed for head and neck cancer patients
7. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
8. UC health news: molecular pathway may predict chemotherapy effectiveness
9. MIT works toward safer gene therapy
10. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
11. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
(Date:9/2/2014)... -- When you accidentally touch a hot oven, you ... basic neural circuits involved in sensing and responding to ... molecular players. , Duke researchers have made a surprising ... in pain in worms, and have built a structural ... in Nature Communications , may help direct new ...
(Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... been accompanied by more years of perfect health, reveals new research ... . Indeed, a 20-year-old today can expect to live one ... a decade ago, even though life expectancy has grown. From ... 85 doubled, from about a 20 percent chance to a 40 ...
... BOSTON Boston University biology professor Richard Primack, ... completed an analysis of the changing arrival dates of ... Henry David Thoreau from the 1850,s. This research builds ... plants in Concord respond rapidly to temperature and are ...
... 2010 Elsevier ( www.elsevier.com ), a world-leading ... and services, today announced that as a result ... HealthMash, is now available on SciVerse Applications beta ... to provide insights to scientific researchers with relevant ...
Cached Biology News:We spend more time sick now than a decade ago 2We spend more time sick now than a decade ago 3WebLib develops application for Elsevier's SciVerse applications 2
(Date:9/2/2014)... Washington, USA (PRWEB) September 02, 2014 ... of Light and Light-based Technologies (IYL 2015) visionary ... from SPIE, the international society for optics and ... presented to Levinson and Dudley along with other awards ... the Society won by James Harrington, during a gala ...
(Date:9/2/2014)... Oregon chemist Geraldine Richmond, have tapped oil and ... called peptoid nanosheets that mimic complex biological mechanisms ... week in a paper placed online ahead of ... Academy of Sciences -- is expected to ... nanosheets that can be used in a broad ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Weisel Partners 2007 Healthcare Conference will be ... the Investors section of the Company,s,website, ... ) The presentation will review recent ...
... ERES ), a leading provider of centralized,electrocardiographic ... Michael J. McKelvey, the Company,s President and,Chief Executive ... will present at the Thomas Weisel Healthcare Conference ... the Phillips Room at The Four Seasons,Hotel in ...
... COMPLETED ... ... LOR; AMEX: LRP), a biopharmaceutical company specializing,in the research and development ... completion of a proof of,concept clinical trial in Acute Myeloid Leukemia ...
Cached Biology Technology:Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th 2eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th 3Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 2Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 3Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 4Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia 5
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: